MarketPulse

Immutep Ltd.

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Plummets 82.6% After Failed Phase III Trial; Class Action Lawsuit Looms

Immutep's stock crashed after discontinuing Phase III TACTI-004 trial for eftilagimod alfa due to futility, prompting securities litigation against the biotech firm.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Plummets 82.6% After Failed Phase III Trial, Sparking Lawsuit

Immutep's $IMMP stock crashed following discontinued Phase III trial for eftilagimod alfa. Rosen Law Firm launches investigation into potential securities claims and class action lawsuit.
IMMPinvestor lossessecurities class action